Eugene Dula, MD

Van Nuys, California 91405

0 studies enrolling now · 2 studies all time

What they study most

Bladder Cancer, Carcinoma in Situ, Prostatic Hyperplasia

Studies at this site

• Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) — Completed
• A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH). — Status unconfirmed